Abstract 5515
Background
EGFR tyrosine kinase inhibitors (EGFR-TKIs) are standard therapy for EGFRm aNSCLC. Upon progression, 50-60% will develop the secondary T790M mutation. Recent trials demonstrated improvement in outcomes with osimertinib over standard platinum-based chemotherapy as 2L therapy for T790M-positive EGFRm aNSCLC. To identify T790M, tumour biopsy or plasma testing is necessary. This study aimed to evaluate biopsy procedures and mutational analysis at two Canadian cancer centres.
Methods
BC Cancer-Vancouver and Cross Cancer Institute performed a retrospective review of pts who signed consent to enroll to the AURA2, AURA3 or ASTRIS studies. Pt characteristics, biopsy method, rebiopsy methods/complications, number of rebiopsies performed, and incidence of the T790M mutation were collected.
Results
84 pts were considered for trial enrolment. 80 signed consent with M:F 32:68%; ECOG 0/1/2: 11/66/23%; smoker/ex-smoker/never smoker: 6/21/73%; exon 19/L858R/other: 60/36/4%; prior curative intent treatment in 18%. 78 pts underwent biopsy, most commonly CT/US-guided biopsy (50%), bronchoscope/EBUS (32%), thoracentesis/surgical biopsy (12%). 3 pts had plasma testing. Type of biopsies were cores (47%), fine needle biopsy (18%), transbronchial biopsy (14%), other (21%). The most common sites for biopsy were lung or nodes (64%). The median number of biopsies performed was 2. Only 8% of pts experienced complications after biopsy. 77% of samples were adequate for T790M testing: 35% performed locally, 65% centrally. Overall, 47 pts were found to have T790M; of which, 44 were enrolled in a trial. Among 40 pts who were ineligible for trials, reasons included: T790M negative (72.5%), decline in performance status/death (15%), inadequate tissue (5%), biopsy refusal, unable to biopsy, and symptomatic brain metastases requiring radiation (2.5% each). Additional data on practice pattern will be presented.
Conclusions
Patients and physicians were amenable to re-biopsy at progression for further tumor characterization and treatment selection. The incidence of complications was low despite the majority being pulmonary biopsies. 23% of the samples were not adequate for molecular analysis.
Clinical trial identification
Legal entity responsible for the study
University of Alberta, Alberta Health Services, Cross Cancer Institute and AstraZeneca.
Funding
AstraZeneca.
Editorial Acknowledgement
Disclosure
Q.S-C. Chu: Honorarium: AstraZeneca, BMS, BI, Eisai, Lily, Merck, Novartis, Roche, Takeda; Research funding: AstraZeneca. N.C. Devost, R. Walton: Employee: AstraZeneca. C. Ho: Honorarium and research funding: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract